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The association of microRNA alterations with progression and treatment outcome has been revealed in different
types of cancers. To find miRNAs involved in imatinib response we performed miRNA microarray followed by
RT-qPCR verification of 9 available diagnostic bone marrow core biopsies from 9 CML patients including 4
imatinib-resistant and 5 imatinib-responder patients. Only one differentially expressed miRNA, miR-181c, was found
when the imatinib-resistant group was compared with imatinib-responders. Significant down-regulation of miR-181c
in imatinib-resistant versus imatinib-responders was confirmed by qRT-PCR. Some miR-181c target genes such as
PBX3, HSP90B1, NMT2 and RAD21 have been associated with drug response.
Keywords: miRNA, CML, Imatinib responseChronic myeloid leukemia (CML) is characterized by
unregulated proliferation of myeloid cells in the bone
marrow that carry the BCR-ABL fusion gene. In most of
the patients, the ABL tyrosine kinase of the fusion protein
is effectively inhibited by the tyrosine kinase inhibitors
(TKIs), but some patients are resistant to TKI therapy.
Whereas the BCR-ABL fusion drives the initial chronic
phase of the disease, the progression of CML involves
additional genomic changes which make leukemia cells
resistant to TKI therapy and independent of BCR-ABL.
Recently, in a variety of cancers the role of microRNAs
(miRNA) in disease progression has been addressed [1].
MiRNAs are potential regulators of drug efficacy, because
they target many important drug-related genes [2].
To understand which miRNAs are associated with the
TKI therapy response, we performed miRNA microarray
in 9 bone marrow core biopsies derived from 9 CML
patients at diagnosis including 5 imatinib-responder and
4 imatinib-resistant patients. The ABL mutations were
not tested at the time of diagnosis, and during the therapy
they were only tested for resistant patients. Three of four
patients developed mutations later during the treatment,
but this occurred 6–10 years after the diagnosis. The study
was conducted in accordance with the principles of the* Correspondence: sakari.knuutila@helsinki.fi
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distribution, and reproduction in any mediumHelsinki Declaration and was approved by the Helsinki
University Central Hospital Ethics Committee. Written
informed consent was obtained from each patient. For
clinical information see Table 1.
From core biopsies, total RNA, including miRNA,
was isolated with the miRNeasy FFPE Mini Kit (Qiagen,
Valencia, CA, USA). To check the quality of total RNA
we used the RNA 6000 chip and for miRNA the small
RNA chip (Agilent Technologies, Santa Clara, CA, USA)
Agilent’s Bioanalyzer. An miRNA microarray system (V3)
(containing 866 human and 89 human viral miRNAs)
(Agilent) was used for miRNA profiling according to
Agilent’s protocol. Based on our previous study, the
core biopsy samples are a reliable source for miRNA
profiling [4].
The raw data were analyzed with GeneSpring Software
v.11.5.0. The data were preprocessed by taking log2 and
normalized by the 75th percentile method. The T-test
was applied to find the most significant differentially
expressed miRNAs (P<0.05 and False discovery rate or
q < 0.05).
Despite the small sample size used in our study—
which indicates the rarity of resistant patients—we found
one miRNA, miR-181c, which is differentially expressed
between imatinib-resistant and imatinib-responder pa-
tients (P=1.41E-6, q=6.1E-4). MiR-181c was validated by
quantitative RT-PCR (qRT-PCR) by the use of the SYBR
Green miScript PCR system (Qiagen) on the Light-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patient characteristics
Patient no. Year of dg Gender Age at dg Sokal score Treatment Treatment response
1. 1996 F 45 7.44 HU, 11/96 IFN, 6/2002 IM, 5/2005 DAS No CgR
2. 1998 F 56 1.37 HU, 3/99 IFN, 04/2002 IM, 08/2006 DAS Min CgR
3. 2010 M 68 1.61 HU, 3/2010 IM, 12/2010 NIL, 6/2011 DAS Min CgR
4. 2008 M 58 1.39 HU, 7/2008 IM, 6/2009 DAS, 3/2010 alloHSCT No CgR
5. 2005 M 48 0.93 HU, 11/2005 IM, 2/2006 IM + IFN CMR
6. 2005 M 58 0.77 11/2005 IM CMR
7. 2004 M 55 0.69 HU, 10/2004 IM, 3/2005 IM + IFN CMR
8. 2006 F 53 0.68 HU, 1/2007 IM CMR
9. 2006 M 52 0.85 HU, 1/2007 IM MMR
In all non-responder patients (patients 1–4) the treatment response to imatinib was failure based on the European Leukemia Net (ELN) criteria [3] (no or minimal
cytogenetic response to imatinib within 12 months after the start of therapy). These patients were subsequently treated with other TKIs (dasatinib/nilotinib), but
no cytogenetic responses were achieved with 2nd generation TKIs either, confirming these patients to be non-responders to multiple TKIs. Patients in the
responder group (patients 5–9) fulfilled the optimal response to imatinib based on ELN criteria. Abbreviations: no number, dg diagnosis, HU hydroxyurea, IFN
interferon, IM imatinib, DAS dasatinib, NIL nilotinib, alloHSCT allogeneic hematopoietic stem cell transplantation, CgR cytogenetic response, min minimal, CMR
complete molecular response, MMR major molecular response.
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Germany). The primer sequence for miR-181c was pur-
chased from Qiagen and the primer was 5' AACAUUCAA
CCUGUCGGUGAGU. The snRNA U6 gene (Qiagen)
served as the normalization control, and relative quantifi-
cation for each miRNA was calculated using the 2−ΔΔCt.
Significant down-regulation of miR-181c (p=0.04) in
imatinib-resistant vs. imatinib-responder patients was
confirmed by qRT-PCR (Figure 1 and Additional file 1:
Figure S1).
In normal conditions, miR-181c is expressed in the
thymus, primary lymphoid organs, brain, lungs, bone
marrow, and spleen [5]. MiR-181 has also been associated
with the differentiation of both hematopoietic B cells [5]
and T cells [6], and myoblasts [7]. MiR-181c is involved in
a tumor-suppression pathway [8] and likely in regulationFigure 1 Average of relative expression level of miR-181c
expression. miR-181c is down-regulated in imatinib-resistant
compared to imatinib-responder samples.of the Rb pathway which mediates cell-growth arrest [9].
Its inhibitory effect on cell growth and increasing apop-
tosis has been observed in glioma cells [8]. In accordance
with our finding, the strong down-regulation of the miR-
181 family, including miR-181c, has been observed in Lyn-
mediated imatinib-resistant CML cells [10]. Similarly,
AML patients with intermediate- or poor-risk subtypes
have been reported to have lower miR-181 levels than do
patients with favorable prognosis [11]. The decreased
expression of this miRNA has also been found in Fanconi
anemia patients, and been involved in the impaired
growth of their hematopoietic progenitors [12]. However,
in two recent studies involving CML patients, no associ-
ation appeared between the miR-181c expression and
imatinib therapy response [13,14]. Furthermore, in CML
patients with blast chrisis, the miR-181c was not differ-
entially expressed, but miR-181a and miR-181b were
upregulated [15].
To study which genes are targeted by miR-181c, we
used Chipster software v.1.4. To reduce false positivity,
target genes needed to be predicted by at least five of
six algorithms, including TargetScan, miRanda, Sanger
miRBase, mirTarget2, Tarbase, and PICTAR (Additional
file 2: Table S1). Some of the miR-181c target genes are
associated with prognosis and drug response, ones such
as PBX3,HSP90B1, NMT2, and RAD21. For example, AML
patients with intermediate- to poor-prognosis subtypes,
who had lower expression of miR-181, conversely showed
an increased level of PBX3 [16]. The up-regulation of
NMT2 and RAD21 contributes to chemoresistance in
osteosarcoma cell lines and also in breast cancers [17,18].
Similarly, high expression of HSP90B1 is associated in
breast cancer with distant metastasis and with decreased
overall and disease-free survival [19]. Moreover, high
HSP90 expression predicts worse overall survival in pa-
tients with acute lymphocytic leukemia [20].
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sistance. Larger sample sizes and further independent
studies, however, are warranted to assess the role of
candidate miRNA and target genes in the molecular
mechanisms underlying resistance in CML.
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